The GeneNav HPV One qPCR Kit is designed for quick initial screening of individuals for the presence of all 14 High Risk human papilloma virus (HPV) subtypes allowing physicians to identify those at risk for cervical cancer. This in vitro diagnostic kit allows for the specific detection and discrimination between HPV 16, HPV 18, and nonspecific pooled detection of the other 12 high risk HPV subtypes (HPV 31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56, HPV 58, HPV 59, HPV 66, and HPV 68). A human ?-Actin internal control is also used in the GeneNav HPV One qPCR Kit to assess specimen quality and ensure the reliability of the HPV detection results.
Product Type:
Fluorescent Probe-based qPCR
Format:
48 Test Kit
Storage Temp:
-25°C to -15°C in a non-frost-free freezer
Applications:
qPCR
Application Details:
Specific detection and discrimination between HPV 16, 18, and non-specific pooled detection of HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
The GeneNav HPV Genotyping qPCR Kit is designed for continuous monitoring of individuals who have been confirmed to be HPV positive with one of the 14 High Risk human papilloma virus (HPV) subtypes. This kit allows physicians to track patients who are at a greater risk of developing cervical cancer by identifying individuals who show persistent infection with the same HPV subtype. This in vitro diagnostic kit allows for the specific detection and discrimination of all 14 High Risk HPV subtypes: HPV 16, HPV 18, HPV 31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56, HPV 58, HPV 59, HPV 66, and HPV 68. A ?-Actin internal control is also used in the GeneNav HPV Genotyping qPCR Kit to assess specimen quality and ensure the reliability of the HPV detection results.
Product Type:
Fluorescent Probe-based qPCR
Format:
24 Test Kit
Storage Temp:
-25°C to -15°C in a non-frost-free freezer
Applications:
qPCR
Application Details:
Specific detection and discrimination between all 14 High Risk HPV Subtypes, including: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.
The GeneNav HPV Complete qPCR Kit utilizes quantitative PCR (qPCR) technology to detect all 14 High Risk human papilloma virus (HPV) subtypes, allowing physicians to identify those at risk for cervical cancer. In addition, HPV Complete enables detection of HPV types 6 and 11 which are considered low risk for cervical cancer, however they are the cause of 90% of all cases of genital warts as well as respiratory papillomatosis. This in vitro diagnostic kit allows for simultaneous detection of HPV 16 or HPV 18, nonspecific pooled detection of the other 12 high risk HPV subtypes (HPV 31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56, HPV 58, HPV 59, HPV 66, and HPV 68), and simultaneous detection of low-risk subtypes HPV 6 or 11. A human ?-Actin internal control is also used in the GeneNav HPV Complete qPCR Kit to assess specimen quality and ensure the reliability of the HPV detection results.
Product Type:
Fluorescent Probe-based qPCR
Format:
48 Test Kit
Storage Temp:
-25°C to -15°C in a non-frost-free freezer
Applications:
qPCR
Application Details:
Simultaneous detection of HPV 16 or HPV 18, nonspecific pooled detection of the other 12 high risk HPV subtypes (HPV 31, HPV 33, HPV 35, HPV 39, HPV 45, HPV 51, HPV 52, HPV 56, HPV 58, HPV 59, HPV 66, and HPV 68), and simultaneous detection of low-risk subtypes HPV 6 or 11.
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumour immunity, as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B-cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumour immunity, as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B-cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumour immunity, as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B-cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Programmed Death 1 (PD-1) is a member of the CD28/CTLA-4 family of T-cell regulators, expressed as a co-receptor on the surface of activated T-cells, B-cells, and macrophages. New studies have suggested that the PD-1/PD-L1 signaling pathway may be linked to anti-tumour immunity, as PD-L1 has been shown to induce apoptosis of activated T-cells or inhibit activity of cytotoxic T-cells. In comparison to CD10 and Bcl-6, PD-1 is expressed by fewer B-cells and has therefore been considered a more specific and useful diagnostic marker for angioimmunoblastic T-cell lymphoma. Therapies targeted toward the PD-1 receptor have shown remarkable clinical responses in patients with various types of cancer, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
T-Cell Immunoglobulin and Mucin-Domain-Containing Molecule-3 (TIM3) is present on T-helper type 1 lymphocytes and other immune cells, including dendritic cells and natural killer cells. TIM3 is overexpressed in CD4+ tumour-infiltrating lymphocytes, including those with non-small cell lung cancer associated with poor prognoses. TIM3 has recently emerged as a potential target for cancer immunotherapy.
T-Cell Immunoglobulin and Mucin-Domain-Containing Molecule-3 (TIM3) is present on T-helper type 1 lymphocytes and other immune cells, including dendritic cells and natural killer cells. TIM3 is overexpressed in CD4+ tumour-infiltrating lymphocytes, including those with non-small cell lung cancer associated with poor prognoses. TIM3 has recently emerged as a potential target for cancer immunotherapy.
T-Cell Immunoglobulin and Mucin-Domain-Containing Molecule-3 (TIM3) is present on T-helper type 1 lymphocytes and other immune cells, including dendritic cells and natural killer cells. TIM3 is overexpressed in CD4+ tumour-infiltrating lymphocytes, including those with non-small cell lung cancer associated with poor prognoses. TIM3 has recently emerged as a potential target for cancer immunotherapy.
T-Cell Immunoglobulin and Mucin-Domain-Containing Molecule-3 (TIM3) is present on T-helper type 1 lymphocytes and other immune cells, including dendritic cells and natural killer cells. TIM3 is overexpressed in CD4+ tumour-infiltrating lymphocytes, including those with non-small cell lung cancer associated with poor prognoses. TIM3 has recently emerged as a potential target for cancer immunotherapy.
Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) is a receptor on T helper cells that functions as an immune checkpoint and downregulator of immune responses. Mutations in CTLA-4 are associated with insulin-dependent diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, systemic lupus erythematosus (SLE), celiac disease, primary biliary cirrhosis, thyroid-associated orbitopathy, multiple sclerosis, and other autoimmune diseases. The spliced variant of CTLA-4 in SLE is present in the patient's serum. Haploinsufficiency of CTLA-4 causes the immune system disorder known as CTLA-4 deficiency or CHAI disease (CTLA-4 haploinsufficiency with autoimmune infiltration).
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC004
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) is a receptor on T helper cells that functions as an immune checkpoint and downregulator of immune responses. Mutations in CTLA-4 are associated with insulin-dependent diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, systemic lupus erythematosus (SLE), celiac disease, primary biliary cirrhosis, thyroid-associated orbitopathy, multiple sclerosis, and other autoimmune diseases. The spliced variant of CTLA-4 in SLE is present in the patient's serum. Haploinsufficiency of CTLA-4 causes the immune system disorder known as CTLA-4 deficiency or CHAI disease (CTLA-4 haploinsufficiency with autoimmune infiltration).
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC004
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) is a receptor on T helper cells that functions as an immune checkpoint and downregulator of immune responses. Mutations in CTLA-4 are associated with insulin-dependent diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, systemic lupus erythematosus (SLE), celiac disease, primary biliary cirrhosis, thyroid-associated orbitopathy, multiple sclerosis, and other autoimmune diseases. The spliced variant of CTLA-4 in SLE is present in the patient's serum. Haploinsufficiency of CTLA-4 causes the immune system disorder known as CTLA-4 deficiency or CHAI disease (CTLA-4 haploinsufficiency with autoimmune infiltration).
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC004
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) is a receptor on T helper cells that functions as an immune checkpoint and downregulator of immune responses. Mutations in CTLA-4 are associated with insulin-dependent diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, systemic lupus erythematosus (SLE), celiac disease, primary biliary cirrhosis, thyroid-associated orbitopathy, multiple sclerosis, and other autoimmune diseases. The spliced variant of CTLA-4 in SLE is present in the patient's serum. Haploinsufficiency of CTLA-4 causes the immune system disorder known as CTLA-4 deficiency or CHAI disease (CTLA-4 haploinsufficiency with autoimmune infiltration).
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
PAX5 is a member of the paired box (PAX) family of transcription factors, which are key regulators in early development. The PAX5 gene encodes the B-cell lineage specific activator protein (BSAP), whose expression is limited to early stages of B-cell differentiation. Anti-PAX5 is useful in differentiating between classic Hodgkin's lymphoma versus multiple myeloma and solitary plasmacytoma, as the protein is expressed in mature and precursor B-cell non-Hodgkin's lymphomas/leukemias while being absent from the other two conditions. Diffuse large B-cell lymphomas are positive for PAX5, with the exception of those with terminal B-cell differentiation, and T-cell neoplasms do not stain with Anti-PAX5.
PAX5 is a member of the paired box (PAX) family of transcription factors, which are key regulators in early development. The PAX5 gene encodes the B-cell lineage specific activator protein (BSAP), whose expression is limited to early stages of B-cell differentiation. Anti-PAX5 is useful in differentiating between classic Hodgkin's lymphoma versus multiple myeloma and solitary plasmacytoma, as the protein is expressed in mature and precursor B-cell non-Hodgkin's lymphomas/leukemias while being absent from the other two conditions. Diffuse large B-cell lymphomas are positive for PAX5, with the exception of those with terminal B-cell differentiation, and T-cell neoplasms do not stain with Anti-PAX5.
PAX5 is a member of the paired box (PAX) family of transcription factors, which are key regulators in early development. The PAX5 gene encodes the B-cell lineage specific activator protein (BSAP), whose expression is limited to early stages of B-cell differentiation. Anti-PAX5 is useful in differentiating between classic Hodgkin's lymphoma versus multiple myeloma and solitary plasmacytoma, as the protein is expressed in mature and precursor B-cell non-Hodgkin's lymphomas/leukemias while being absent from the other two conditions. Diffuse large B-cell lymphomas are positive for PAX5, with the exception of those with terminal B-cell differentiation, and T-cell neoplasms do not stain with Anti-PAX5.
PAX5 is a member of the paired box (PAX) family of transcription factors, which are key regulators in early development. The PAX5 gene encodes the B-cell lineage specific activator protein (BSAP), whose expression is limited to early stages of B-cell differentiation. Anti-PAX5 is useful in differentiating between classic Hodgkin's lymphoma versus multiple myeloma and solitary plasmacytoma, as the protein is expressed in mature and precursor B-cell non-Hodgkin's lymphomas/leukemias while being absent from the other two conditions. Diffuse large B-cell lymphomas are positive for PAX5, with the exception of those with terminal B-cell differentiation, and T-cell neoplasms do not stain with Anti-PAX5.
MutS Homolog 6 (MSH6) is a protein involved in the mismatch repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Studies have shown that mutations in MSH6, when co-indicated with mutations in MSH1 and MSH2, contribute to the development of sporadic colorectal carcinoma. Use of Anti-MSH2 is optimized when paired with MSH6, MLH1, and PMS2 in an IHC panel.
MutS Homolog 6 (MSH6) is a protein involved in the mismatch repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Studies have shown that mutations in MSH6, when co-indicated with mutations in MSH1 and MSH2, contribute to the development of sporadic colorectal carcinoma. Use of Anti-MSH2 is optimized when paired with MSH6, MLH1, and PMS2 in an IHC panel.
MutS Homolog 6 (MSH6) is a protein involved in the mismatch repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Studies have shown that mutations in MSH6, when co-indicated with mutations in MSH1 and MSH2, contribute to the development of sporadic colorectal carcinoma. Use of Anti-MSH2 is optimized when paired with MSH6, MLH1, and PMS2 in an IHC panel.
MutS Homolog 6 (MSH6) is a protein involved in the mismatch repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Studies have shown that mutations in MSH6, when co-indicated with mutations in MSH1 and MSH2, contribute to the development of sporadic colorectal carcinoma. Use of Anti-MSH2 is optimized when paired with MSH6, MLH1, and PMS2 in an IHC panel.
Cytokeratin 7 (CK7) is a type II keratin which is present in transitional, ductal, glandular, and biliary duct epithelial cells. Cytokeratin 7 is a useful marker for distinguishing between carcinomas of the lung, breast, endometrium, and urothelia (positive stain) from carcinomas of the colon and prostate (negative stain). Cytokeratin 7 is present is nearly all primary lung adenocarcinomas, and is a useful marker in the differential diagnosis of ovarian neoplasms. Anti-Cytokeratin 7 does not stain intermediate filament.
Cytokeratin 7 (CK7) is a type II keratin which is present in transitional, ductal, glandular, and biliary duct epithelial cells. Cytokeratin 7 is a useful marker for distinguishing between carcinomas of the lung, breast, endometrium, and urothelia (positive stain) from carcinomas of the colon and prostate (negative stain). Cytokeratin 7 is present is nearly all primary lung adenocarcinomas, and is a useful marker in the differential diagnosis of ovarian neoplasms. Anti-Cytokeratin 7 does not stain intermediate filament.
Cytokeratin 7 (CK7) is a type II keratin which is present in transitional, ductal, glandular, and biliary duct epithelial cells. Cytokeratin 7 is a useful marker for distinguishing between carcinomas of the lung, breast, endometrium, and urothelia (positive stain) from carcinomas of the colon and prostate (negative stain). Cytokeratin 7 is present is nearly all primary lung adenocarcinomas, and is a useful marker in the differential diagnosis of ovarian neoplasms. Anti-Cytokeratin 7 does not stain intermediate filament.
Cytokeratin 7 (CK7) is a type II keratin which is present in transitional, ductal, glandular, and biliary duct epithelial cells. Cytokeratin 7 is a useful marker for distinguishing between carcinomas of the lung, breast, endometrium, and urothelia (positive stain) from carcinomas of the colon and prostate (negative stain). Cytokeratin 7 is present is nearly all primary lung adenocarcinomas, and is a useful marker in the differential diagnosis of ovarian neoplasms. Anti-Cytokeratin 7 does not stain intermediate filament.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
SRY (Sex Determining Region Y)-Box 10 (SOX-10), also known as Transcription Factor SOX-10, is a nuclear transcription factor that acts in regulation of embryonic development and in the specification and differentiation of cells of melanocytic lineage. SOX-10 is diffusely expressed in neurofibromas and schwannomas, and mutations in the SOX-10 gene are linked to Waardenburg-Shah and Waardenburg-Hirschsprung's disease. Anti-SOX-10 has been shown to be sensitive for conventional, spindled, and desmoplastic melanoma, and has been used to detect metastatic melanoma and nodal capsular nevus in sentinel lymph nodes.
SRY (Sex Determining Region Y)-Box 10 (SOX-10), also known as Transcription Factor SOX-10, is a nuclear transcription factor that acts in regulation of embryonic development and in the specification and differentiation of cells of melanocytic lineage. SOX-10 is diffusely expressed in neurofibromas and schwannomas, and mutations in the SOX-10 gene are linked to Waardenburg-Shah and Waardenburg-Hirschsprung's disease. Anti-SOX-10 has been shown to be sensitive for conventional, spindled, and desmoplastic melanoma, and has been used to detect metastatic melanoma and nodal capsular nevus in sentinel lymph nodes.
SRY (Sex Determining Region Y)-Box 10 (SOX-10), also known as Transcription Factor SOX-10, is a nuclear transcription factor that acts in regulation of embryonic development and in the specification and differentiation of cells of melanocytic lineage. SOX-10 is diffusely expressed in neurofibromas and schwannomas, and mutations in the SOX-10 gene are linked to Waardenburg-Shah and Waardenburg-Hirschsprung's disease. Anti-SOX-10 has been shown to be sensitive for conventional, spindled, and desmoplastic melanoma, and has been used to detect metastatic melanoma and nodal capsular nevus in sentinel lymph nodes.
SRY (Sex Determining Region Y)-Box 10 (SOX-10), also known as Transcription Factor SOX-10, is a nuclear transcription factor that acts in regulation of embryonic development and in the specification and differentiation of cells of melanocytic lineage. SOX-10 is diffusely expressed in neurofibromas and schwannomas, and mutations in the SOX-10 gene are linked to Waardenburg-Shah and Waardenburg-Hirschsprung's disease. Anti-SOX-10 has been shown to be sensitive for conventional, spindled, and desmoplastic melanoma, and has been used to detect metastatic melanoma and nodal capsular nevus in sentinel lymph nodes.
SRY (Sex Determining Region Y)-Box 11 (SOX11), also known as Transcription Factor SOX11, is a nuclear transcription factor that acts in regulation of embryonic development, cell differentiation, and the development of the human central nervous system. SOX11 is expressed in medulloblastoma and glioma, and has been indicated as a marker for both Cyclin D1-positive and -negative mantle cell lymphomas, Burkitt's lymphoma, and lymphoblastic lymphoma.
SRY (Sex Determining Region Y)-Box 11 (SOX11), also known as Transcription Factor SOX11, is a nuclear transcription factor that acts in regulation of embryonic development, cell differentiation, and the development of the human central nervous system. SOX11 is expressed in medulloblastoma and glioma, and has been indicated as a marker for both Cyclin D1-positive and -negative mantle cell lymphomas, Burkitt's lymphoma, and lymphoblastic lymphoma.
SRY (Sex Determining Region Y)-Box 11 (SOX11), also known as Transcription Factor SOX11, is a nuclear transcription factor that acts in regulation of embryonic development, cell differentiation, and the development of the human central nervous system. SOX11 is expressed in medulloblastoma and glioma, and has been indicated as a marker for both Cyclin D1-positive and -negative mantle cell lymphomas, Burkitt's lymphoma, and lymphoblastic lymphoma.
SRY (Sex Determining Region Y)-Box 11 (SOX11), also known as Transcription Factor SOX11, is a nuclear transcription factor that acts in regulation of embryonic development, cell differentiation, and the development of the human central nervous system. SOX11 is expressed in medulloblastoma and glioma, and has been indicated as a marker for both Cyclin D1-positive and -negative mantle cell lymphomas, Burkitt's lymphoma, and lymphoblastic lymphoma.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
Product Type:
Primary Antibody
Antibody Type:
Polyclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC012
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
Product Type:
Primary Antibody
Antibody Type:
Polyclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC012
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
Product Type:
Primary Antibody
Antibody Type:
Polyclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC012
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 13 (CD13) is a transmembrane protein that is overexpressed in both hematological and solid malignancies, including Acute Myeloid Leukemia (AML). Although hypogranular variants of AML are difficult to distinguish from other AML subtypes due to the morphology, the diagnosis of this variant is possible through using a panel of CD13, CD16, CD33, CD34, and CD117. Alternatively, a panel of CD13, CD34, CD43, CD68, CD117, CD163, lysozyme, and MPO is very useful for accurately diagnosing myeloid sarcoma and distinguishing it from large cell lymphoma, undifferentiated carcinoma, lymphoblastic lymphoma, malignant melanoma, Burkitt's lymphoma, extra-medullary hematopoiesis, and inflammation. Since CD13 is expressed in both normal and neoplastic liver tissues, CD13 staining is useful for distinguishing between hepatocellular carcinoma and non-hepatocellular neoplasms.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC013
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Liver
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 13 (CD13) is a transmembrane protein that is overexpressed in both hematological and solid malignancies, including Acute Myeloid Leukemia (AML). Although hypogranular variants of AML are difficult to distinguish from other AML subtypes due to the morphology, the diagnosis of this variant is possible through using a panel of CD13, CD16, CD33, CD34, and CD117. Alternatively, a panel of CD13, CD34, CD43, CD68, CD117, CD163, lysozyme, and MPO is very useful for accurately diagnosing myeloid sarcoma and distinguishing it from large cell lymphoma, undifferentiated carcinoma, lymphoblastic lymphoma, malignant melanoma, Burkitt's lymphoma, extra-medullary hematopoiesis, and inflammation. Since CD13 is expressed in both normal and neoplastic liver tissues, CD13 staining is useful for distinguishing between hepatocellular carcinoma and non-hepatocellular neoplasms.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC013
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Liver
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 13 (CD13) is a transmembrane protein that is overexpressed in both hematological and solid malignancies, including Acute Myeloid Leukemia (AML). Although hypogranular variants of AML are difficult to distinguish from other AML subtypes due to the morphology, the diagnosis of this variant is possible through using a panel of CD13, CD16, CD33, CD34, and CD117. Alternatively, a panel of CD13, CD34, CD43, CD68, CD117, CD163, lysozyme, and MPO is very useful for accurately diagnosing myeloid sarcoma and distinguishing it from large cell lymphoma, undifferentiated carcinoma, lymphoblastic lymphoma, malignant melanoma, Burkitt's lymphoma, extra-medullary hematopoiesis, and inflammation. Since CD13 is expressed in both normal and neoplastic liver tissues, CD13 staining is useful for distinguishing between hepatocellular carcinoma and non-hepatocellular neoplasms.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC013
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Liver
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 13 (CD13) is a transmembrane protein that is overexpressed in both hematological and solid malignancies, including Acute Myeloid Leukemia (AML). Although hypogranular variants of AML are difficult to distinguish from other AML subtypes due to the morphology, the diagnosis of this variant is possible through using a panel of CD13, CD16, CD33, CD34, and CD117. Alternatively, a panel of CD13, CD34, CD43, CD68, CD117, CD163, lysozyme, and MPO is very useful for accurately diagnosing myeloid sarcoma and distinguishing it from large cell lymphoma, undifferentiated carcinoma, lymphoblastic lymphoma, malignant melanoma, Burkitt's lymphoma, extra-medullary hematopoiesis, and inflammation. Since CD13 is expressed in both normal and neoplastic liver tissues, CD13 staining is useful for distinguishing between hepatocellular carcinoma and non-hepatocellular neoplasms.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cytokeratin 18 (CK18) is present in simple, glandular, and transitional epithelial cells, but is absent in stratified epithelial cells. CK18 usually multimerizes with Cytokeratin 8, and Anti-Cytokeratin 18 is useful for detecting adenocarcinomas of simple and glandular epithelium origin, as well as poorly differentiated squamous carcinoma cells.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC018
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast, Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cytokeratin 18 (CK18) is present in simple, glandular, and transitional epithelial cells, but is absent in stratified epithelial cells. CK18 usually multimerizes with Cytokeratin 8, and Anti-Cytokeratin 18 is useful for detecting adenocarcinomas of simple and glandular epithelium origin, as well as poorly differentiated squamous carcinoma cells.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC018
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast, Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cytokeratin 18 (CK18) is present in simple, glandular, and transitional epithelial cells, but is absent in stratified epithelial cells. CK18 usually multimerizes with Cytokeratin 8, and Anti-Cytokeratin 18 is useful for detecting adenocarcinomas of simple and glandular epithelium origin, as well as poorly differentiated squamous carcinoma cells.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC018
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Breast, Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cytokeratin 18 (CK18) is present in simple, glandular, and transitional epithelial cells, but is absent in stratified epithelial cells. CK18 usually multimerizes with Cytokeratin 8, and Anti-Cytokeratin 18 is useful for detecting adenocarcinomas of simple and glandular epithelium origin, as well as poorly differentiated squamous carcinoma cells.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cytokeratin 19 (CK19) forms intermediate filaments found in the intracytoplasmic cytoskeleton of epithelial tissue and provides mechanical support. Anti-Cytokeratin 19 stains epithelia and epithelial malignancies such as carcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Cytokeratin 19 is a useful marker for distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. This differentiation is improved when stained in combination with Cytokeratin 7, CAM5.2, Ber-EP4/MOC31, Hep-Par1, and TTF1. Cytokeratin 19 staining can also be used to recognize thyroid papillary carcinomas.
Cytokeratin 19 (CK19) forms intermediate filaments found in the intracytoplasmic cytoskeleton of epithelial tissue and provides mechanical support. Anti-Cytokeratin 19 stains epithelia and epithelial malignancies such as carcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Cytokeratin 19 is a useful marker for distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. This differentiation is improved when stained in combination with Cytokeratin 7, CAM5.2, Ber-EP4/MOC31, Hep-Par1, and TTF1. Cytokeratin 19 staining can also be used to recognize thyroid papillary carcinomas.
Cytokeratin 19 (CK19) forms intermediate filaments found in the intracytoplasmic cytoskeleton of epithelial tissue and provides mechanical support. Anti-Cytokeratin 19 stains epithelia and epithelial malignancies such as carcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Cytokeratin 19 is a useful marker for distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. This differentiation is improved when stained in combination with Cytokeratin 7, CAM5.2, Ber-EP4/MOC31, Hep-Par1, and TTF1. Cytokeratin 19 staining can also be used to recognize thyroid papillary carcinomas.
Cytokeratin 19 (CK19) forms intermediate filaments found in the intracytoplasmic cytoskeleton of epithelial tissue and provides mechanical support. Anti-Cytokeratin 19 stains epithelia and epithelial malignancies such as carcinomas of the colon, stomach, pancreas, biliary tract, liver, and breast. Cytokeratin 19 is a useful marker for distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. This differentiation is improved when stained in combination with Cytokeratin 7, CAM5.2, Ber-EP4/MOC31, Hep-Par1, and TTF1. Cytokeratin 19 staining can also be used to recognize thyroid papillary carcinomas.
Cytokeratin 20 (CK20) forms intermediate filaments and is normally present in gastric and intestinal epithelium, urothelium, and Merkel cells. Anti-Cytokeratin 20 is used for distinguishing specific types of urinary tract epithelial cells and malignant epithelia. Anti-Cytokeratin 20 stains tissues of the colon, stomach, pancreas, biliary system adenocarcinomas, transitional-cell, mucinous ovarian tumours, and Merkel cell carcinomas. Non-mucinous tumours of the ovary and adenocarcinomas of the breast, lung, endometrium, squamous cell, and small cell type are not stained by Anti-Cytokeratin 20.
Cytokeratin 20 (CK20) forms intermediate filaments and is normally present in gastric and intestinal epithelium, urothelium, and Merkel cells. Anti-Cytokeratin 20 is used for distinguishing specific types of urinary tract epithelial cells and malignant epithelia. Anti-Cytokeratin 20 stains tissues of the colon, stomach, pancreas, biliary system adenocarcinomas, transitional-cell, mucinous ovarian tumours, and Merkel cell carcinomas. Non-mucinous tumours of the ovary and adenocarcinomas of the breast, lung, endometrium, squamous cell, and small cell type are not stained by Anti-Cytokeratin 20.
Cytokeratin 20 (CK20) forms intermediate filaments and is normally present in gastric and intestinal epithelium, urothelium, and Merkel cells. Anti-Cytokeratin 20 is used for distinguishing specific types of urinary tract epithelial cells and malignant epithelia. Anti-Cytokeratin 20 stains tissues of the colon, stomach, pancreas, biliary system adenocarcinomas, transitional-cell, mucinous ovarian tumours, and Merkel cell carcinomas. Non-mucinous tumours of the ovary and adenocarcinomas of the breast, lung, endometrium, squamous cell, and small cell type are not stained by Anti-Cytokeratin 20.
Cytokeratin 20 (CK20) forms intermediate filaments and is normally present in gastric and intestinal epithelium, urothelium, and Merkel cells. Anti-Cytokeratin 20 is used for distinguishing specific types of urinary tract epithelial cells and malignant epithelia. Anti-Cytokeratin 20 stains tissues of the colon, stomach, pancreas, biliary system adenocarcinomas, transitional-cell, mucinous ovarian tumours, and Merkel cell carcinomas. Non-mucinous tumours of the ovary and adenocarcinomas of the breast, lung, endometrium, squamous cell, and small cell type are not stained by Anti-Cytokeratin 20.
Cluster of Differentiation 23 (CD23) is found on interleukin-4 activated B-cells, activated macrophages, eosinophils, and follicular dendritic cells, and is a receptor for IgE, an antibody involved in parasitic immunity. CD23 is present on Reed-Sternberg cells in Hodgkin's disease. Follicular dendritic cells and activated B-lymphocytes produce strong staining in germinal centers and weak patterns in mantle zone B-cells. CD23 is helpful in differentiating chronic lymphocytic leukemia from mantle cell leukemia. Small B-cell lymphomas are sometimes positive, while precursor B- and T-lymphomas, myeloid neoplasms, and mature T-cell lymphomas stain negatively with Anti-CD23.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC023
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil, Lymph Node, Cll/Sll
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 23 (CD23) is found on interleukin-4 activated B-cells, activated macrophages, eosinophils, and follicular dendritic cells, and is a receptor for IgE, an antibody involved in parasitic immunity. CD23 is present on Reed-Sternberg cells in Hodgkin's disease. Follicular dendritic cells and activated B-lymphocytes produce strong staining in germinal centers and weak patterns in mantle zone B-cells. CD23 is helpful in differentiating chronic lymphocytic leukemia from mantle cell leukemia. Small B-cell lymphomas are sometimes positive, while precursor B- and T-lymphomas, myeloid neoplasms, and mature T-cell lymphomas stain negatively with Anti-CD23.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC023
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil, Lymph Node, Cll/Sll
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 23 (CD23) is found on interleukin-4 activated B-cells, activated macrophages, eosinophils, and follicular dendritic cells, and is a receptor for IgE, an antibody involved in parasitic immunity. CD23 is present on Reed-Sternberg cells in Hodgkin's disease. Follicular dendritic cells and activated B-lymphocytes produce strong staining in germinal centers and weak patterns in mantle zone B-cells. CD23 is helpful in differentiating chronic lymphocytic leukemia from mantle cell leukemia. Small B-cell lymphomas are sometimes positive, while precursor B- and T-lymphomas, myeloid neoplasms, and mature T-cell lymphomas stain negatively with Anti-CD23.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC023
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Tonsil, Lymph Node, Cll/Sll
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 23 (CD23) is found on interleukin-4 activated B-cells, activated macrophages, eosinophils, and follicular dendritic cells, and is a receptor for IgE, an antibody involved in parasitic immunity. CD23 is present on Reed-Sternberg cells in Hodgkin's disease. Follicular dendritic cells and activated B-lymphocytes produce strong staining in germinal centers and weak patterns in mantle zone B-cells. CD23 is helpful in differentiating chronic lymphocytic leukemia from mantle cell leukemia. Small B-cell lymphomas are sometimes positive, while precursor B- and T-lymphomas, myeloid neoplasms, and mature T-cell lymphomas stain negatively with Anti-CD23.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
MutS Homolog 6 (MSH6) is a protein involved in the mismatch repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Studies have shown that mutations in MSH6, when co-indicated with mutations in MSH1 and MSH2, contribute to the development of sporadic colorectal carcinoma. Use of Anti-MSH2 is optimized when paired with MSH6, MLH1, and PMS2 in an IHC panel.
MutS Homolog 6 (MSH6) is a protein involved in the mismatch repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Studies have shown that mutations in MSH6, when co-indicated with mutations in MSH1 and MSH2, contribute to the development of sporadic colorectal carcinoma. Use of Anti-MSH2 is optimized when paired with MSH6, MLH1, and PMS2 in an IHC panel.
MutS Homolog 6 (MSH6) is a protein involved in the mismatch repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Studies have shown that mutations in MSH6, when co-indicated with mutations in MSH1 and MSH2, contribute to the development of sporadic colorectal carcinoma. Use of Anti-MSH2 is optimized when paired with MSH6, MLH1, and PMS2 in an IHC panel.
MutS Homolog 6 (MSH6) is a protein involved in the mismatch repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Studies have shown that mutations in MSH6, when co-indicated with mutations in MSH1 and MSH2, contribute to the development of sporadic colorectal carcinoma. Use of Anti-MSH2 is optimized when paired with MSH6, MLH1, and PMS2 in an IHC panel.
p27, also known as p27<sup>Kip1</sup>, is a cyclin-dependent kinase inhibitor that binds to and inhibits cyclin-dependent kinases, thereby regulating progression from G1 to S phase. Decreased expression of p27 is linked to poor prognosis in renal-cell carcinoma, colon carcinoma, small breast carcinomas, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in papillary carcinoma of the thyroid, and is associated with a more aggressive phenotype of carcinoma in the cervix.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC027
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p27, also known as p27<sup>Kip1</sup>, is a cyclin-dependent kinase inhibitor that binds to and inhibits cyclin-dependent kinases, thereby regulating progression from G1 to S phase. Decreased expression of p27 is linked to poor prognosis in renal-cell carcinoma, colon carcinoma, small breast carcinomas, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in papillary carcinoma of the thyroid, and is associated with a more aggressive phenotype of carcinoma in the cervix.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC027
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p27, also known as p27<sup>Kip1</sup>, is a cyclin-dependent kinase inhibitor that binds to and inhibits cyclin-dependent kinases, thereby regulating progression from G1 to S phase. Decreased expression of p27 is linked to poor prognosis in renal-cell carcinoma, colon carcinoma, small breast carcinomas, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in papillary carcinoma of the thyroid, and is associated with a more aggressive phenotype of carcinoma in the cervix.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC027
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p27, also known as p27<sup>Kip1</sup>, is a cyclin-dependent kinase inhibitor that binds to and inhibits cyclin-dependent kinases, thereby regulating progression from G1 to S phase. Decreased expression of p27 is linked to poor prognosis in renal-cell carcinoma, colon carcinoma, small breast carcinomas, non-small-cell lung carcinoma, hepatocellular carcinoma, multiple myeloma, lymph node metastases in papillary carcinoma of the thyroid, and is associated with a more aggressive phenotype of carcinoma in the cervix.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
Cluster of Differentiation 31 (CD31) is present on hematopoietic stem cells (HSCs), and its expression is used to determine the concentration of HSCs in research studies and for bone marrow transplantation. Anti-CD31 is very specific and sensitive for endothelial cells and does not stain non-vascular tumours, therefore CD31 staining is used to recognize the vascular origins of neoplasms.
Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
Cluster of Differentiation 34 (CD34) is a transmembrane glycoprotein expressed on hematopoietic stem and progenitor cells, vascular endothelium, embryonic fibroblasts, and rare glial cells in nervous tissue. CD34 is the most used marker for characterizing blasts in leukemia. CD34 is also present in some soft tissue tumours including solitary fibrous tumours and gastrointestinal stromal tumours. Proliferating endothelial cells seem to upregulate CD34 expression. Although specificity is low, Anti-CD34 reacts positively with more than 85% of angiosarcoma and Kaposi’s sarcoma.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
ROS1 serves as a receptor tyrosine kinase. Gene rearrangement events involving ROS1 have been described in lung and other cancers, and such tumors have been found to be remarkably responsive to small molecule tyrosine kinase inhibitors. Multiple studies have demonstrated an incidence of approximately 1% in lung cancers, demonstrated oncogenicity, and showed that inhibition of tumor cells bearing ROS1 gene fusions by crizotinib or other ROS1 tyrosine kinase inhibitors was effective in vitro.
ROS1 serves as a receptor tyrosine kinase. Gene rearrangement events involving ROS1 have been described in lung and other cancers, and such tumors have been found to be remarkably responsive to small molecule tyrosine kinase inhibitors. Multiple studies have demonstrated an incidence of approximately 1% in lung cancers, demonstrated oncogenicity, and showed that inhibition of tumor cells bearing ROS1 gene fusions by crizotinib or other ROS1 tyrosine kinase inhibitors was effective in vitro.
ROS1 serves as a receptor tyrosine kinase. Gene rearrangement events involving ROS1 have been described in lung and other cancers, and such tumors have been found to be remarkably responsive to small molecule tyrosine kinase inhibitors. Multiple studies have demonstrated an incidence of approximately 1% in lung cancers, demonstrated oncogenicity, and showed that inhibition of tumor cells bearing ROS1 gene fusions by crizotinib or other ROS1 tyrosine kinase inhibitors was effective in vitro.
ROS1 serves as a receptor tyrosine kinase. Gene rearrangement events involving ROS1 have been described in lung and other cancers, and such tumors have been found to be remarkably responsive to small molecule tyrosine kinase inhibitors. Multiple studies have demonstrated an incidence of approximately 1% in lung cancers, demonstrated oncogenicity, and showed that inhibition of tumor cells bearing ROS1 gene fusions by crizotinib or other ROS1 tyrosine kinase inhibitors was effective in vitro.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
The HER2/neu (c-erbB-2) proto-oncogene is a transmembrane receptor tyrosine kinase that is clinically indicated in a number of carcinomas. Overexpression of the c-erbB-2 protein has been associated with ductal breast cancer, as well as pulmonary and gastric adenocarcinomas. A correlation between HER2 and p53 has also been documented, as overexpression of both proteins has been associated with early invasion and metastasis in bladder cancer.
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC044
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Benign Urothelium
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC044
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Benign Urothelium
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC044
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Benign Urothelium
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX8 is expressed in simple ovarian inclusion cysts and non-ciliated mucosal cells of the fallopian tubes, but is absent from normal ovarian surface epithelial cells. Mutations in the PAX8 gene are linked to thyroid follicular carcinomas, atypical thyroid adenomas, and thyroid dysgenesis. Reports have associated PAX8 expression with renal carcinoma, nephroblastoma, and seminoma, and have indicated PAX8 as a useful marker for renal epithelial tumours, ovarian cancer, and for differential diagnoses in lung and neck tumours. Anti-PAX8 can be useful in determining the primary site of invasive micropapillary carcinomas of ovary from bladder, lung, and breast, when used in adjunct with a panel of organ-specific markers such as uroplakin, mammaglobin, and TTF-1.
PAX-2 is a homeogene that is expressed during kidney developing. Its expression was observed within the metanephric mesenchyma and plays a key role in mesenchyma-epithelium conversion. PAX-2 has been demonstrated to be expressed in renal carcinoma cell lines and has a potential role in the proliferation of these cell lines. Anti-PAX-2 antibodies may be useful in differentiating ovarian serous papilary carcinomas from breast carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC052
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Renal Cell Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
PAX-2 is a homeogene that is expressed during kidney developing. Its expression was observed within the metanephric mesenchyma and plays a key role in mesenchyma-epithelium conversion. PAX-2 has been demonstrated to be expressed in renal carcinoma cell lines and has a potential role in the proliferation of these cell lines. Anti-PAX-2 antibodies may be useful in differentiating ovarian serous papilary carcinomas from breast carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC052
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Renal Cell Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
PAX-2 is a homeogene that is expressed during kidney developing. Its expression was observed within the metanephric mesenchyma and plays a key role in mesenchyma-epithelium conversion. PAX-2 has been demonstrated to be expressed in renal carcinoma cell lines and has a potential role in the proliferation of these cell lines. Anti-PAX-2 antibodies may be useful in differentiating ovarian serous papilary carcinomas from breast carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC052
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Renal Cell Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
PAX-2 is a homeogene that is expressed during kidney developing. Its expression was observed within the metanephric mesenchyma and plays a key role in mesenchyma-epithelium conversion. PAX-2 has been demonstrated to be expressed in renal carcinoma cell lines and has a potential role in the proliferation of these cell lines. Anti-PAX-2 antibodies may be useful in differentiating ovarian serous papilary carcinomas from breast carcinomas.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p53, also known as Tumour Protein 53 or TP53, is a tumour suppressor and transcription factor that functions in a number of anti-cancer activities including DNA repair, cell-cycle arrest, and apoptosis in response to DNA damage or other stressors. Mutations in p53 are linked to a number of malignant tumours, including those of the breast, ovary, bladder, colon, lung, and melanoma. Anti-p53 staining has been used to detect intratubular germ cell neoplasia, and also to distinguish between uterine serous carcinoma and endometrioid carcinoma.
p53, also known as Tumour Protein 53 or TP53, is a tumour suppressor and transcription factor that functions in a number of anti-cancer activities including DNA repair, cell-cycle arrest, and apoptosis in response to DNA damage or other stressors. Mutations in p53 are linked to a number of malignant tumours, including those of the breast, ovary, bladder, colon, lung, and melanoma. Anti-p53 staining has been used to detect intratubular germ cell neoplasia, and also to distinguish between uterine serous carcinoma and endometrioid carcinoma.
p53, also known as Tumour Protein 53 or TP53, is a tumour suppressor and transcription factor that functions in a number of anti-cancer activities including DNA repair, cell-cycle arrest, and apoptosis in response to DNA damage or other stressors. Mutations in p53 are linked to a number of malignant tumours, including those of the breast, ovary, bladder, colon, lung, and melanoma. Anti-p53 staining has been used to detect intratubular germ cell neoplasia, and also to distinguish between uterine serous carcinoma and endometrioid carcinoma.
p53, also known as Tumour Protein 53 or TP53, is a tumour suppressor and transcription factor that functions in a number of anti-cancer activities including DNA repair, cell-cycle arrest, and apoptosis in response to DNA damage or other stressors. Mutations in p53 are linked to a number of malignant tumours, including those of the breast, ovary, bladder, colon, lung, and melanoma. Anti-p53 staining has been used to detect intratubular germ cell neoplasia, and also to distinguish between uterine serous carcinoma and endometrioid carcinoma.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
p57<sup>Kip2</sup>, also known as p57, is a tumour suppressor protein that causes cell cycle arrest at G1 by binding to G1 cyclin-CDK complexes. The p57<sup>Kip2</sup> gene is a potential tumour suppressor target as the gene is located in a chromosomal region implicated in sporadic cancers, Wilms' tumour, and Beckwith Wiedemann syndrome. Anti-p57<sup>Kip2</sup> labels many cytotrophoblast nuclei and stromal cells in normal placenta, and is useful in differentiating between complete hydatidiform mole and partial hydatidiform mole or hydropic abortion.
p57<sup>Kip2</sup>, also known as p57, is a tumour suppressor protein that causes cell cycle arrest at G1 by binding to G1 cyclin-CDK complexes. The p57<sup>Kip2</sup> gene is a potential tumour suppressor target as the gene is located in a chromosomal region implicated in sporadic cancers, Wilms' tumour, and Beckwith Wiedemann syndrome. Anti-p57<sup>Kip2</sup> labels many cytotrophoblast nuclei and stromal cells in normal placenta, and is useful in differentiating between complete hydatidiform mole and partial hydatidiform mole or hydropic abortion.
p57<sup>Kip2</sup>, also known as p57, is a tumour suppressor protein that causes cell cycle arrest at G1 by binding to G1 cyclin-CDK complexes. The p57<sup>Kip2</sup> gene is a potential tumour suppressor target as the gene is located in a chromosomal region implicated in sporadic cancers, Wilms' tumour, and Beckwith Wiedemann syndrome. Anti-p57<sup>Kip2</sup> labels many cytotrophoblast nuclei and stromal cells in normal placenta, and is useful in differentiating between complete hydatidiform mole and partial hydatidiform mole or hydropic abortion.
p57<sup>Kip2</sup>, also known as p57, is a tumour suppressor protein that causes cell cycle arrest at G1 by binding to G1 cyclin-CDK complexes. The p57<sup>Kip2</sup> gene is a potential tumour suppressor target as the gene is located in a chromosomal region implicated in sporadic cancers, Wilms' tumour, and Beckwith Wiedemann syndrome. Anti-p57<sup>Kip2</sup> labels many cytotrophoblast nuclei and stromal cells in normal placenta, and is useful in differentiating between complete hydatidiform mole and partial hydatidiform mole or hydropic abortion.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Anti-p40 recognizes squamous and basal cells, the shortest variant of p53, and ΔNp63 (an isoform of p63). p40 has been indicated as an alternative to p63 for the detection of Squamous Cell Carcinoma (SqCC), offering the advantage of eliminating potential misinterpretation of a positive adenocarcinoma as a SqCC.
Cluster of Differentiation 61 (CD61), also known as Glycoprotein IIIa or GPIIIa, is an antigen expressed on megakaryocytes, platelets, myeloid cells, monocytes, endothelial cells, smooth muscle cells, and macrophages. It is involved in platelet aggregation and acts as a receptor for fibrinogen, fibronectin, von Willebrand factor, and vitronectin. Anti-CD61 is used for identifying megakaryocytopoiesis, as seen in megakaryoblastic leukemias, myelodysplastic disorders, and acute myeloid leukemias. CD61 is also indicated as a marker for platelet adhesion in advanced atherosclerosis and has been reported in the identification of fat embolism in pulmonary tissue.
Cluster of Differentiation 61 (CD61), also known as Glycoprotein IIIa or GPIIIa, is an antigen expressed on megakaryocytes, platelets, myeloid cells, monocytes, endothelial cells, smooth muscle cells, and macrophages. It is involved in platelet aggregation and acts as a receptor for fibrinogen, fibronectin, von Willebrand factor, and vitronectin. Anti-CD61 is used for identifying megakaryocytopoiesis, as seen in megakaryoblastic leukemias, myelodysplastic disorders, and acute myeloid leukemias. CD61 is also indicated as a marker for platelet adhesion in advanced atherosclerosis and has been reported in the identification of fat embolism in pulmonary tissue.
Cluster of Differentiation 61 (CD61), also known as Glycoprotein IIIa or GPIIIa, is an antigen expressed on megakaryocytes, platelets, myeloid cells, monocytes, endothelial cells, smooth muscle cells, and macrophages. It is involved in platelet aggregation and acts as a receptor for fibrinogen, fibronectin, von Willebrand factor, and vitronectin. Anti-CD61 is used for identifying megakaryocytopoiesis, as seen in megakaryoblastic leukemias, myelodysplastic disorders, and acute myeloid leukemias. CD61 is also indicated as a marker for platelet adhesion in advanced atherosclerosis and has been reported in the identification of fat embolism in pulmonary tissue.
Cluster of Differentiation 61 (CD61), also known as Glycoprotein IIIa or GPIIIa, is an antigen expressed on megakaryocytes, platelets, myeloid cells, monocytes, endothelial cells, smooth muscle cells, and macrophages. It is involved in platelet aggregation and acts as a receptor for fibrinogen, fibronectin, von Willebrand factor, and vitronectin. Anti-CD61 is used for identifying megakaryocytopoiesis, as seen in megakaryoblastic leukemias, myelodysplastic disorders, and acute myeloid leukemias. CD61 is also indicated as a marker for platelet adhesion in advanced atherosclerosis and has been reported in the identification of fat embolism in pulmonary tissue.
KBA.62, also known as Melanoma Associated Antigen, is used to detect an antigen present in melanocytic tumours, such as melanomas, due to its proven sensitivity and specificity. The antibody can also be used to distinguish between junctional nevus and intradermal nevus cells, and fetal melanocytes versus normal adult melanocytes. Studies have shown KBA.62 to be highly useful in differentiating between metastatic amelanotic melanoma and a number of poorly differentiated carcinomas, large cell lymphomas, sarcomas, and spindle cell carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC062
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
KBA.62, also known as Melanoma Associated Antigen, is used to detect an antigen present in melanocytic tumours, such as melanomas, due to its proven sensitivity and specificity. The antibody can also be used to distinguish between junctional nevus and intradermal nevus cells, and fetal melanocytes versus normal adult melanocytes. Studies have shown KBA.62 to be highly useful in differentiating between metastatic amelanotic melanoma and a number of poorly differentiated carcinomas, large cell lymphomas, sarcomas, and spindle cell carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC062
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
KBA.62, also known as Melanoma Associated Antigen, is used to detect an antigen present in melanocytic tumours, such as melanomas, due to its proven sensitivity and specificity. The antibody can also be used to distinguish between junctional nevus and intradermal nevus cells, and fetal melanocytes versus normal adult melanocytes. Studies have shown KBA.62 to be highly useful in differentiating between metastatic amelanotic melanoma and a number of poorly differentiated carcinomas, large cell lymphomas, sarcomas, and spindle cell carcinomas.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC062
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Melanoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
KBA.62, also known as Melanoma Associated Antigen, is used to detect an antigen present in melanocytic tumours, such as melanomas, due to its proven sensitivity and specificity. The antibody can also be used to distinguish between junctional nevus and intradermal nevus cells, and fetal melanocytes versus normal adult melanocytes. Studies have shown KBA.62 to be highly useful in differentiating between metastatic amelanotic melanoma and a number of poorly differentiated carcinomas, large cell lymphomas, sarcomas, and spindle cell carcinomas.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p63 is a tumour suppressor protein that is very similar to p53 in structure and function, while being homologous to p73. p63 is important in development and differentiation, and has been identified as a useful marker for distinguishing between lung squamous cell carcinomas and adenocarcinomas. Anti-p63 is also used to differentiate between benign and malignant prostate and breast lesions, due to its labeling of the nuclei of myoepithelial cells in both tissue types.
p63 is a tumour suppressor protein that is very similar to p53 in structure and function, while being homologous to p73. p63 is important in development and differentiation, and has been identified as a useful marker for distinguishing between lung squamous cell carcinomas and adenocarcinomas. Anti-p63 is also used to differentiate between benign and malignant prostate and breast lesions, due to its labeling of the nuclei of myoepithelial cells in both tissue types.
p63 is a tumour suppressor protein that is very similar to p53 in structure and function, while being homologous to p73. p63 is important in development and differentiation, and has been identified as a useful marker for distinguishing between lung squamous cell carcinomas and adenocarcinomas. Anti-p63 is also used to differentiate between benign and malignant prostate and breast lesions, due to its labeling of the nuclei of myoepithelial cells in both tissue types.
p63 is a tumour suppressor protein that is very similar to p53 in structure and function, while being homologous to p73. p63 is important in development and differentiation, and has been identified as a useful marker for distinguishing between lung squamous cell carcinomas and adenocarcinomas. Anti-p63 is also used to differentiate between benign and malignant prostate and breast lesions, due to its labeling of the nuclei of myoepithelial cells in both tissue types.
Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) is a receptor on T helper cells that functions as an immune checkpoint and downregulator of immune responses. Mutations in CTLA-4 are associated with insulin-dependent diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, systemic lupus erythematosus (SLE), celiac disease, primary biliary cirrhosis, thyroid-associated orbitopathy, multiple sclerosis, and other autoimmune diseases. The spliced variant of CTLA-4 in SLE is present in the patient's serum. Haploinsufficiency of CTLA-4 causes the immune system disorder known as CTLA-4 deficiency or CHAI disease (CTLA-4 haploinsufficiency with autoimmune infiltration).
Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) is a receptor on T helper cells that functions as an immune checkpoint and downregulator of immune responses. Mutations in CTLA-4 are associated with insulin-dependent diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, systemic lupus erythematosus (SLE), celiac disease, primary biliary cirrhosis, thyroid-associated orbitopathy, multiple sclerosis, and other autoimmune diseases. The spliced variant of CTLA-4 in SLE is present in the patient's serum. Haploinsufficiency of CTLA-4 causes the immune system disorder known as CTLA-4 deficiency or CHAI disease (CTLA-4 haploinsufficiency with autoimmune infiltration).
Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) is a receptor on T helper cells that functions as an immune checkpoint and downregulator of immune responses. Mutations in CTLA-4 are associated with insulin-dependent diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, systemic lupus erythematosus (SLE), celiac disease, primary biliary cirrhosis, thyroid-associated orbitopathy, multiple sclerosis, and other autoimmune diseases. The spliced variant of CTLA-4 in SLE is present in the patient's serum. Haploinsufficiency of CTLA-4 causes the immune system disorder known as CTLA-4 deficiency or CHAI disease (CTLA-4 haploinsufficiency with autoimmune infiltration).
Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) is a receptor on T helper cells that functions as an immune checkpoint and downregulator of immune responses. Mutations in CTLA-4 are associated with insulin-dependent diabetes mellitus, Hashimoto's thyroiditis, Graves' disease, systemic lupus erythematosus (SLE), celiac disease, primary biliary cirrhosis, thyroid-associated orbitopathy, multiple sclerosis, and other autoimmune diseases. The spliced variant of CTLA-4 in SLE is present in the patient's serum. Haploinsufficiency of CTLA-4 causes the immune system disorder known as CTLA-4 deficiency or CHAI disease (CTLA-4 haploinsufficiency with autoimmune infiltration).
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Cluster of Differentiation 56 (CD56), also known as Neural-Cell Adhesion Molecule (NCAM), is a glycoprotein involved in synaptic plasticity, cell-cell adhesion, neurite outgrowth, learning, and memory. NCAM is expressed in normal neurons, glia, natural killer cells, activated T-cells, brain and cerebellum, neuroendocrine tissues, and skeletal muscle. Anti-CD56 recognizes a number of tumours including myeloma, myeloid leukemia, natural killer/T-cell lymphomas, neuroendocrine tumours, pancreatic acinar-cell carcinoma, pheochromocytoma, and Wilm's tumour. CD56 is detectable in neoplasms that are neuroectodermally-derived, such as retinoblastoma, medulloblastomas, astrocytomas, small cell carcinomas, and neuroblastomas. It has also been linked to rhabdomyosarcoma, a tumour that is mesodermally-derived.
Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumours, including those of the brain, breast, cervix, and prostate.
Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumours, including those of the brain, breast, cervix, and prostate.
Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumours, including those of the brain, breast, cervix, and prostate.
Ki-67 is a nuclear, non-histone protein that is expressed only during active phases of the cell cycle (G1, S, G2 and M), but not in the resting phases (G0 and G1 early phase). Although the antigen has also been associated with ribosomal RNA transcription, it is strongly linked to cell proliferation and has thus been indicated as an effective marker in grading the proliferation rate of tumours, including those of the brain, breast, cervix, and prostate.
Cluster of Differentiation 68 (CD68) is a heavily glycosylated transmembrane antigen that is detected in lysosomes, tissue macrophages, Langerhans cells, dendritic cells, monocytes, Kupffer cells, osteoclasts, and granulocytes. Anti-CD68 may be useful in identifying myelomonocytic and histiocytic tumours, and for differentiating between malignant fibrous histiocytoma and other pleomorphic sarcomas. However, other lysosome-rich cells may also stain, since Anti-CD68 detects a formalin-resistant epitope that may be associated with lysosomal granules.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC068
Antibody Isotype:
IgG3
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 68 (CD68) is a heavily glycosylated transmembrane antigen that is detected in lysosomes, tissue macrophages, Langerhans cells, dendritic cells, monocytes, Kupffer cells, osteoclasts, and granulocytes. Anti-CD68 may be useful in identifying myelomonocytic and histiocytic tumours, and for differentiating between malignant fibrous histiocytoma and other pleomorphic sarcomas. However, other lysosome-rich cells may also stain, since Anti-CD68 detects a formalin-resistant epitope that may be associated with lysosomal granules.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC068
Antibody Isotype:
IgG3
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 68 (CD68) is a heavily glycosylated transmembrane antigen that is detected in lysosomes, tissue macrophages, Langerhans cells, dendritic cells, monocytes, Kupffer cells, osteoclasts, and granulocytes. Anti-CD68 may be useful in identifying myelomonocytic and histiocytic tumours, and for differentiating between malignant fibrous histiocytoma and other pleomorphic sarcomas. However, other lysosome-rich cells may also stain, since Anti-CD68 detects a formalin-resistant epitope that may be associated with lysosomal granules.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC068
Antibody Isotype:
IgG3
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 68 (CD68) is a heavily glycosylated transmembrane antigen that is detected in lysosomes, tissue macrophages, Langerhans cells, dendritic cells, monocytes, Kupffer cells, osteoclasts, and granulocytes. Anti-CD68 may be useful in identifying myelomonocytic and histiocytic tumours, and for differentiating between malignant fibrous histiocytoma and other pleomorphic sarcomas. However, other lysosome-rich cells may also stain, since Anti-CD68 detects a formalin-resistant epitope that may be associated with lysosomal granules.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 71 (CD71), also known as Transferrin Receptor Protein 1 (TfR1) or the transferrin receptor, is a cell surface proliferation marker that is involved in the cellular uptake of iron. CD71 is most highly expressed in early erythroid precursors and is fully absent from mature erythrocytes; CD71 is therefore highly useful as a marker for erythroid components within bone marrow biopsy specimens, without interference from mature erythrocytes. CD71 expression has been indicated in invasive breast carcinoma with acquired resistance to tamoxifen, and has been linked to poor prognosis in ER+/luminal-like breast cancer. Anti-CD71 is used in the determination of erythroid leukemia, benign erythroid proliferative disorders, and myelodysplastic syndrome.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC071
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Bone Marrow
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 71 (CD71), also known as Transferrin Receptor Protein 1 (TfR1) or the transferrin receptor, is a cell surface proliferation marker that is involved in the cellular uptake of iron. CD71 is most highly expressed in early erythroid precursors and is fully absent from mature erythrocytes; CD71 is therefore highly useful as a marker for erythroid components within bone marrow biopsy specimens, without interference from mature erythrocytes. CD71 expression has been indicated in invasive breast carcinoma with acquired resistance to tamoxifen, and has been linked to poor prognosis in ER+/luminal-like breast cancer. Anti-CD71 is used in the determination of erythroid leukemia, benign erythroid proliferative disorders, and myelodysplastic syndrome.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC071
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Bone Marrow
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 71 (CD71), also known as Transferrin Receptor Protein 1 (TfR1) or the transferrin receptor, is a cell surface proliferation marker that is involved in the cellular uptake of iron. CD71 is most highly expressed in early erythroid precursors and is fully absent from mature erythrocytes; CD71 is therefore highly useful as a marker for erythroid components within bone marrow biopsy specimens, without interference from mature erythrocytes. CD71 expression has been indicated in invasive breast carcinoma with acquired resistance to tamoxifen, and has been linked to poor prognosis in ER+/luminal-like breast cancer. Anti-CD71 is used in the determination of erythroid leukemia, benign erythroid proliferative disorders, and myelodysplastic syndrome.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC071
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Bone Marrow
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 71 (CD71), also known as Transferrin Receptor Protein 1 (TfR1) or the transferrin receptor, is a cell surface proliferation marker that is involved in the cellular uptake of iron. CD71 is most highly expressed in early erythroid precursors and is fully absent from mature erythrocytes; CD71 is therefore highly useful as a marker for erythroid components within bone marrow biopsy specimens, without interference from mature erythrocytes. CD71 expression has been indicated in invasive breast carcinoma with acquired resistance to tamoxifen, and has been linked to poor prognosis in ER+/luminal-like breast cancer. Anti-CD71 is used in the determination of erythroid leukemia, benign erythroid proliferative disorders, and myelodysplastic syndrome.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Tumour-Associated Glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer pathologies. Anti-TAG-72 can be useful for detecting some adenocarcinomas and non-neoplastic tissues. This diagnostic grade TAG-72 IVD antibody is useful for identifying adenocarcinomas in positive staining, but in mesotheliomas no staining is observed.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC072
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Tumour-Associated Glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer pathologies. Anti-TAG-72 can be useful for detecting some adenocarcinomas and non-neoplastic tissues. This diagnostic grade TAG-72 IVD antibody is useful for identifying adenocarcinomas in positive staining, but in mesotheliomas no staining is observed.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC072
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Tumour-Associated Glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer pathologies. Anti-TAG-72 can be useful for detecting some adenocarcinomas and non-neoplastic tissues. This diagnostic grade TAG-72 IVD antibody is useful for identifying adenocarcinomas in positive staining, but in mesotheliomas no staining is observed.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC072
Antibody Isotype:
IgG1, kappa
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lung Adenocarcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Tumour-Associated Glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer pathologies. Anti-TAG-72 can be useful for detecting some adenocarcinomas and non-neoplastic tissues. This diagnostic grade TAG-72 IVD antibody is useful for identifying adenocarcinomas in positive staining, but in mesotheliomas no staining is observed.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 73 (CD73), also known as Ecto-5'-Nucleotidase (ecto-5'-NT), is a cell surface enzyme found in most tissues. CD73 catalyzes the breakdown of AMP to adenosine, thereby modulating inflammatory and T-cell responses. Reports have implicated CD73 expression in tumour progression and carcinogenesis, as CD73 is a key regulatory molecule in the proliferation, migration, and invasion of cancer cells <em>in vitro</em>, as well as tumour angiogenesis and tumour immune escape <em>in vivo</em>. Due to this key involvement in cancer, CD73 has become an appealing target for cancer immunotherapy. CD73 expression has also been linked to favourable prognosis in breast carcinoma.
Cluster of Differentiation 73 (CD73), also known as Ecto-5'-Nucleotidase (ecto-5'-NT), is a cell surface enzyme found in most tissues. CD73 catalyzes the breakdown of AMP to adenosine, thereby modulating inflammatory and T-cell responses. Reports have implicated CD73 expression in tumour progression and carcinogenesis, as CD73 is a key regulatory molecule in the proliferation, migration, and invasion of cancer cells <em>in vitro</em>, as well as tumour angiogenesis and tumour immune escape <em>in vivo</em>. Due to this key involvement in cancer, CD73 has become an appealing target for cancer immunotherapy. CD73 expression has also been linked to favourable prognosis in breast carcinoma.
Cluster of Differentiation 73 (CD73), also known as Ecto-5'-Nucleotidase (ecto-5'-NT), is a cell surface enzyme found in most tissues. CD73 catalyzes the breakdown of AMP to adenosine, thereby modulating inflammatory and T-cell responses. Reports have implicated CD73 expression in tumour progression and carcinogenesis, as CD73 is a key regulatory molecule in the proliferation, migration, and invasion of cancer cells <em>in vitro</em>, as well as tumour angiogenesis and tumour immune escape <em>in vivo</em>. Due to this key involvement in cancer, CD73 has become an appealing target for cancer immunotherapy. CD73 expression has also been linked to favourable prognosis in breast carcinoma.
Cluster of Differentiation 73 (CD73), also known as Ecto-5'-Nucleotidase (ecto-5'-NT), is a cell surface enzyme found in most tissues. CD73 catalyzes the breakdown of AMP to adenosine, thereby modulating inflammatory and T-cell responses. Reports have implicated CD73 expression in tumour progression and carcinogenesis, as CD73 is a key regulatory molecule in the proliferation, migration, and invasion of cancer cells <em>in vitro</em>, as well as tumour angiogenesis and tumour immune escape <em>in vivo</em>. Due to this key involvement in cancer, CD73 has become an appealing target for cancer immunotherapy. CD73 expression has also been linked to favourable prognosis in breast carcinoma.
Calcitonin is a polypeptide hormone formed by the proteolytic cleavage of a larger prepropeptide. It is produced primarily by the parafollicular C-cells of the thyroid, and is involved in the regulation of calcium and phosphorus metabolism. It decreases the level of calcium and phosphate ions in blood by promoting the incorporation of these ions into bones, as well as inhibiting renal tubular cell reabsorption. Calcitonin expression is found in C-cell hyperplasia and medullary thyroid carcinomas. It is a useful marker in the identification of C-cell proliferative abnormalities, and for distinguishing medullary carcinoma from papillary and follicular thyroid cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC521
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Thyroid, Thyroid Medullary Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Calcitonin is a polypeptide hormone formed by the proteolytic cleavage of a larger prepropeptide. It is produced primarily by the parafollicular C-cells of the thyroid, and is involved in the regulation of calcium and phosphorus metabolism. It decreases the level of calcium and phosphate ions in blood by promoting the incorporation of these ions into bones, as well as inhibiting renal tubular cell reabsorption. Calcitonin expression is found in C-cell hyperplasia and medullary thyroid carcinomas. It is a useful marker in the identification of C-cell proliferative abnormalities, and for distinguishing medullary carcinoma from papillary and follicular thyroid cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC521
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Thyroid, Thyroid Medullary Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Calcitonin is a polypeptide hormone formed by the proteolytic cleavage of a larger prepropeptide. It is produced primarily by the parafollicular C-cells of the thyroid, and is involved in the regulation of calcium and phosphorus metabolism. It decreases the level of calcium and phosphate ions in blood by promoting the incorporation of these ions into bones, as well as inhibiting renal tubular cell reabsorption. Calcitonin expression is found in C-cell hyperplasia and medullary thyroid carcinomas. It is a useful marker in the identification of C-cell proliferative abnormalities, and for distinguishing medullary carcinoma from papillary and follicular thyroid cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC521
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Thyroid, Thyroid Medullary Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Calcitonin is a polypeptide hormone formed by the proteolytic cleavage of a larger prepropeptide. It is produced primarily by the parafollicular C-cells of the thyroid, and is involved in the regulation of calcium and phosphorus metabolism. It decreases the level of calcium and phosphate ions in blood by promoting the incorporation of these ions into bones, as well as inhibiting renal tubular cell reabsorption. Calcitonin expression is found in C-cell hyperplasia and medullary thyroid carcinomas. It is a useful marker in the identification of C-cell proliferative abnormalities, and for distinguishing medullary carcinoma from papillary and follicular thyroid cancer.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 79a (CD79a) is a molecule that dimerizes with CD79b to form the B-cell antigen receptor complex that enables antigen presentation. CD79a is specifically expressed in B lineage cell lines including early progenitors, pre-B and mature B-cell lines, normal resting B-lymphocytes, and polyclonally activated B-cell blasts. Since Anti-CD79a and Anti-CD20 both react positively with lymphomas in many of the same cases, Anti-CD79a is frequently used in conjunction with Anti-CD20. In comparison to CD20, CD79a has a greater likelihood of staining plasma cell myeloma and some endothelia. CD79a also frequently stains acute promyelocytic leukemia (FAB-M3), but infrequently stains other types of myeloid leukemia.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC079
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 79a (CD79a) is a molecule that dimerizes with CD79b to form the B-cell antigen receptor complex that enables antigen presentation. CD79a is specifically expressed in B lineage cell lines including early progenitors, pre-B and mature B-cell lines, normal resting B-lymphocytes, and polyclonally activated B-cell blasts. Since Anti-CD79a and Anti-CD20 both react positively with lymphomas in many of the same cases, Anti-CD79a is frequently used in conjunction with Anti-CD20. In comparison to CD20, CD79a has a greater likelihood of staining plasma cell myeloma and some endothelia. CD79a also frequently stains acute promyelocytic leukemia (FAB-M3), but infrequently stains other types of myeloid leukemia.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC079
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 79a (CD79a) is a molecule that dimerizes with CD79b to form the B-cell antigen receptor complex that enables antigen presentation. CD79a is specifically expressed in B lineage cell lines including early progenitors, pre-B and mature B-cell lines, normal resting B-lymphocytes, and polyclonally activated B-cell blasts. Since Anti-CD79a and Anti-CD20 both react positively with lymphomas in many of the same cases, Anti-CD79a is frequently used in conjunction with Anti-CD20. In comparison to CD20, CD79a has a greater likelihood of staining plasma cell myeloma and some endothelia. CD79a also frequently stains acute promyelocytic leukemia (FAB-M3), but infrequently stains other types of myeloid leukemia.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC079
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 79a (CD79a) is a molecule that dimerizes with CD79b to form the B-cell antigen receptor complex that enables antigen presentation. CD79a is specifically expressed in B lineage cell lines including early progenitors, pre-B and mature B-cell lines, normal resting B-lymphocytes, and polyclonally activated B-cell blasts. Since Anti-CD79a and Anti-CD20 both react positively with lymphomas in many of the same cases, Anti-CD79a is frequently used in conjunction with Anti-CD20. In comparison to CD20, CD79a has a greater likelihood of staining plasma cell myeloma and some endothelia. CD79a also frequently stains acute promyelocytic leukemia (FAB-M3), but infrequently stains other types of myeloid leukemia.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Desmoglein-3 Antibody (DSG3) is a component of desmosomes in vertebrate epithelial cells. It identifies pulmonary squamous cell carcinomas from other types of lung cancer with a highly specificity and sensitivity. Studies show the upregulation of DSG3 correlated with metastasis in a number of cancers including lung cancers. The expression of DSG3 indicates a poor prognosis and portends a more aggressive clinical outcome.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC083
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Skin Cancer
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Desmoglein-3 Antibody (DSG3) is a component of desmosomes in vertebrate epithelial cells. It identifies pulmonary squamous cell carcinomas from other types of lung cancer with a highly specificity and sensitivity. Studies show the upregulation of DSG3 correlated with metastasis in a number of cancers including lung cancers. The expression of DSG3 indicates a poor prognosis and portends a more aggressive clinical outcome.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC083
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Skin Cancer
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Desmoglein-3 Antibody (DSG3) is a component of desmosomes in vertebrate epithelial cells. It identifies pulmonary squamous cell carcinomas from other types of lung cancer with a highly specificity and sensitivity. Studies show the upregulation of DSG3 correlated with metastasis in a number of cancers including lung cancers. The expression of DSG3 indicates a poor prognosis and portends a more aggressive clinical outcome.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC083
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Skin Cancer
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Desmoglein-3 Antibody (DSG3) is a component of desmosomes in vertebrate epithelial cells. It identifies pulmonary squamous cell carcinomas from other types of lung cancer with a highly specificity and sensitivity. Studies show the upregulation of DSG3 correlated with metastasis in a number of cancers including lung cancers. The expression of DSG3 indicates a poor prognosis and portends a more aggressive clinical outcome.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 99 (CD99) is a glycosylated transmembrane protein expressed by lymphocytes, cortical thymocytes, granulosa cells of the ovary, pancreatic islet cells, Sertoli cells, and endothelial cells. CD99 produces diffuse membrane staining patterns on nearly all Ewing's sarcoma and primitive peripheral neuroectodermal tumours. CD99 may be found in synovial sarcoma, neuroendocrine carcinoma, acute myeloid leukemia, mesenchymal chondrosarcoma, lymphoblastic lymphoma, small round blue cell tumours, solitary fibrous tumours, vascular tumours, and myeloid sarcoma. It produces heterogeneous staining patterns which must be accompanied by other antibody staining for a final diagnosis.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC099
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Ewings Sarcoma, Pancreas
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 99 (CD99) is a glycosylated transmembrane protein expressed by lymphocytes, cortical thymocytes, granulosa cells of the ovary, pancreatic islet cells, Sertoli cells, and endothelial cells. CD99 produces diffuse membrane staining patterns on nearly all Ewing's sarcoma and primitive peripheral neuroectodermal tumours. CD99 may be found in synovial sarcoma, neuroendocrine carcinoma, acute myeloid leukemia, mesenchymal chondrosarcoma, lymphoblastic lymphoma, small round blue cell tumours, solitary fibrous tumours, vascular tumours, and myeloid sarcoma. It produces heterogeneous staining patterns which must be accompanied by other antibody staining for a final diagnosis.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC099
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Ewings Sarcoma, Pancreas
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 99 (CD99) is a glycosylated transmembrane protein expressed by lymphocytes, cortical thymocytes, granulosa cells of the ovary, pancreatic islet cells, Sertoli cells, and endothelial cells. CD99 produces diffuse membrane staining patterns on nearly all Ewing's sarcoma and primitive peripheral neuroectodermal tumours. CD99 may be found in synovial sarcoma, neuroendocrine carcinoma, acute myeloid leukemia, mesenchymal chondrosarcoma, lymphoblastic lymphoma, small round blue cell tumours, solitary fibrous tumours, vascular tumours, and myeloid sarcoma. It produces heterogeneous staining patterns which must be accompanied by other antibody staining for a final diagnosis.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC099
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Ewings Sarcoma, Pancreas
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 99 (CD99) is a glycosylated transmembrane protein expressed by lymphocytes, cortical thymocytes, granulosa cells of the ovary, pancreatic islet cells, Sertoli cells, and endothelial cells. CD99 produces diffuse membrane staining patterns on nearly all Ewing's sarcoma and primitive peripheral neuroectodermal tumours. CD99 may be found in synovial sarcoma, neuroendocrine carcinoma, acute myeloid leukemia, mesenchymal chondrosarcoma, lymphoblastic lymphoma, small round blue cell tumours, solitary fibrous tumours, vascular tumours, and myeloid sarcoma. It produces heterogeneous staining patterns which must be accompanied by other antibody staining for a final diagnosis.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
S-100 is a low-molecular weight protein found in Schwann cells, melanocytes, glial cells, histiocytes, lipocytes, skeletal and cardiac muscle, chondrocytes, adipocytes, myoepithelial cells, macrophages, Langerhans cells, dendritic cells, and keratinocytes. S-100 is a useful marker for Schwann cell-derived tumours and a number of well-differentiated tumours of the salivary gland, adipose and cartilaginous tissue. Anti-S-100 is used to detect melanomas, histiocytosis X, malignant peripheral nerve sheath tumours, and clear cell sarcomas.
S-100 is a low-molecular weight protein found in Schwann cells, melanocytes, glial cells, histiocytes, lipocytes, skeletal and cardiac muscle, chondrocytes, adipocytes, myoepithelial cells, macrophages, Langerhans cells, dendritic cells, and keratinocytes. S-100 is a useful marker for Schwann cell-derived tumours and a number of well-differentiated tumours of the salivary gland, adipose and cartilaginous tissue. Anti-S-100 is used to detect melanomas, histiocytosis X, malignant peripheral nerve sheath tumours, and clear cell sarcomas.
S-100 is a low-molecular weight protein found in Schwann cells, melanocytes, glial cells, histiocytes, lipocytes, skeletal and cardiac muscle, chondrocytes, adipocytes, myoepithelial cells, macrophages, Langerhans cells, dendritic cells, and keratinocytes. S-100 is a useful marker for Schwann cell-derived tumours and a number of well-differentiated tumours of the salivary gland, adipose and cartilaginous tissue. Anti-S-100 is used to detect melanomas, histiocytosis X, malignant peripheral nerve sheath tumours, and clear cell sarcomas.
S-100 is a low-molecular weight protein found in Schwann cells, melanocytes, glial cells, histiocytes, lipocytes, skeletal and cardiac muscle, chondrocytes, adipocytes, myoepithelial cells, macrophages, Langerhans cells, dendritic cells, and keratinocytes. S-100 is a useful marker for Schwann cell-derived tumours and a number of well-differentiated tumours of the salivary gland, adipose and cartilaginous tissue. Anti-S-100 is used to detect melanomas, histiocytosis X, malignant peripheral nerve sheath tumours, and clear cell sarcomas.
LAG3 (Lymphocyte-activation gene 3) was discovered in 1990 and was previously designated as CD223. LAG3 is a cell surface molecule expressed by activated T cells, natural killer cells, B cells and plasmacytoiddendritic cells. It binds to major histocompatibility complex (MHC) class II molecules and serves as an immune checkpoint receptor. LAG3 negatively regulates cellular proliferation, activation and homeostasisof T cells, and plays a role in Treg suppressive function. LAG3 also helps maintain CD8+ T cells in atolerogenic state and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. LAG3 expression was detected in tumor infiltrating lymphocytes. IHC revealed LAG3 expression was distributed on lymphocytes scattered in renal cell carcinoma, melanoma and lymphomas. They were also detected in the tumor stroma as well as in the peritumoral tissue. LAG3 is the target of various drug development programs for cancer and autoimmune disorders. In soluble form, it is also being developed as a cancer drug in its own right.
LAG3 (Lymphocyte-activation gene 3) was discovered in 1990 and was previously designated as CD223. LAG3 is a cell surface molecule expressed by activated T cells, natural killer cells, B cells and plasmacytoiddendritic cells. It binds to major histocompatibility complex (MHC) class II molecules and serves as an immune checkpoint receptor. LAG3 negatively regulates cellular proliferation, activation and homeostasisof T cells, and plays a role in Treg suppressive function. LAG3 also helps maintain CD8+ T cells in atolerogenic state and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. LAG3 expression was detected in tumor infiltrating lymphocytes. IHC revealed LAG3 expression was distributed on lymphocytes scattered in renal cell carcinoma, melanoma and lymphomas. They were also detected in the tumor stroma as well as in the peritumoral tissue. LAG3 is the target of various drug development programs for cancer and autoimmune disorders. In soluble form, it is also being developed as a cancer drug in its own right.
LAG3 (Lymphocyte-activation gene 3) was discovered in 1990 and was previously designated as CD223. LAG3 is a cell surface molecule expressed by activated T cells, natural killer cells, B cells and plasmacytoiddendritic cells. It binds to major histocompatibility complex (MHC) class II molecules and serves as an immune checkpoint receptor. LAG3 negatively regulates cellular proliferation, activation and homeostasisof T cells, and plays a role in Treg suppressive function. LAG3 also helps maintain CD8+ T cells in atolerogenic state and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. LAG3 expression was detected in tumor infiltrating lymphocytes. IHC revealed LAG3 expression was distributed on lymphocytes scattered in renal cell carcinoma, melanoma and lymphomas. They were also detected in the tumor stroma as well as in the peritumoral tissue. LAG3 is the target of various drug development programs for cancer and autoimmune disorders. In soluble form, it is also being developed as a cancer drug in its own right.
LAG3 (Lymphocyte-activation gene 3) was discovered in 1990 and was previously designated as CD223. LAG3 is a cell surface molecule expressed by activated T cells, natural killer cells, B cells and plasmacytoiddendritic cells. It binds to major histocompatibility complex (MHC) class II molecules and serves as an immune checkpoint receptor. LAG3 negatively regulates cellular proliferation, activation and homeostasisof T cells, and plays a role in Treg suppressive function. LAG3 also helps maintain CD8+ T cells in atolerogenic state and, working with PD-1, helps maintain CD8 exhaustion during chronic viral infection. LAG3 expression was detected in tumor infiltrating lymphocytes. IHC revealed LAG3 expression was distributed on lymphocytes scattered in renal cell carcinoma, melanoma and lymphomas. They were also detected in the tumor stroma as well as in the peritumoral tissue. LAG3 is the target of various drug development programs for cancer and autoimmune disorders. In soluble form, it is also being developed as a cancer drug in its own right.
B7H4 is a glycosylated transmembrane protein of the B7 family. It binds to activated T cells to moderate the T cell responses via cell cycle arrest in the T cell. Reverse signaling can induce either cell cycle arrest or apoptosis in the B7H4 expressing cell. B7H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC104
Antibody Isotype:
IgG2b
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
B7H4 is a glycosylated transmembrane protein of the B7 family. It binds to activated T cells to moderate the T cell responses via cell cycle arrest in the T cell. Reverse signaling can induce either cell cycle arrest or apoptosis in the B7H4 expressing cell. B7H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC104
Antibody Isotype:
IgG2b
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
B7H4 is a glycosylated transmembrane protein of the B7 family. It binds to activated T cells to moderate the T cell responses via cell cycle arrest in the T cell. Reverse signaling can induce either cell cycle arrest or apoptosis in the B7H4 expressing cell. B7H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC104
Antibody Isotype:
IgG2b
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Breast
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
B7H4 is a glycosylated transmembrane protein of the B7 family. It binds to activated T cells to moderate the T cell responses via cell cycle arrest in the T cell. Reverse signaling can induce either cell cycle arrest or apoptosis in the B7H4 expressing cell. B7H4 is up-regulated in several carcinomas in correlation with tumor progression and metastasis. A soluble form of B7H4 is elevated in the serum of ovarian cancer, renal cell carcinoma, and rheumatoid arthritis patients, also in correlation with advanced disease status.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
The p16 (p16<sup>INK4A</sup>) protein is a cyclin-dependent kinase (CDK) inhibitor that plays an important regulatory role in the cell cycle. By controlling the transition between the G1 and S phases through regulation of retinoblastoma protein, p16 decelerates cellular differentiation and therefore acts as a tumor suppressor, making it the key marker in several human cancers including head and neck cancer, perianal lesions, melanomas, gliomas, lymphomas, and some types of leukemia. p16 is also clinically indicated in carcinomas of the esophagus, pancreas, lung, biliary tract, liver, colon, and urinary bladder.
p120 Catenin is a nucleolar protein belonging to the armadillo protein family, which is involved in cell-cell adhesion and signal transduction. p120 Catenin is associated with proliferation, and is found in the majority of human malignant tumours, while remaining absent from resting normal cells. Anti-p120 Catenin is useful in differentiating between ductal and lobular neoplasia in the breast, and strong staining with Anti-p120 Catenin is associated with discohesive infiltrative morphology in gastric and colonic carcinoma. Accumulation of p120 Catenin in the cytoplasm has been linked to lung cancer, pancreatic cancer, and gastric cancer, and is correlated to poor prognosis in colon cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC120
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lobular Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p120 Catenin is a nucleolar protein belonging to the armadillo protein family, which is involved in cell-cell adhesion and signal transduction. p120 Catenin is associated with proliferation, and is found in the majority of human malignant tumours, while remaining absent from resting normal cells. Anti-p120 Catenin is useful in differentiating between ductal and lobular neoplasia in the breast, and strong staining with Anti-p120 Catenin is associated with discohesive infiltrative morphology in gastric and colonic carcinoma. Accumulation of p120 Catenin in the cytoplasm has been linked to lung cancer, pancreatic cancer, and gastric cancer, and is correlated to poor prognosis in colon cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC120
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lobular Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p120 Catenin is a nucleolar protein belonging to the armadillo protein family, which is involved in cell-cell adhesion and signal transduction. p120 Catenin is associated with proliferation, and is found in the majority of human malignant tumours, while remaining absent from resting normal cells. Anti-p120 Catenin is useful in differentiating between ductal and lobular neoplasia in the breast, and strong staining with Anti-p120 Catenin is associated with discohesive infiltrative morphology in gastric and colonic carcinoma. Accumulation of p120 Catenin in the cytoplasm has been linked to lung cancer, pancreatic cancer, and gastric cancer, and is correlated to poor prognosis in colon cancer.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC120
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Lobular Breast Carcinoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
p120 Catenin is a nucleolar protein belonging to the armadillo protein family, which is involved in cell-cell adhesion and signal transduction. p120 Catenin is associated with proliferation, and is found in the majority of human malignant tumours, while remaining absent from resting normal cells. Anti-p120 Catenin is useful in differentiating between ductal and lobular neoplasia in the breast, and strong staining with Anti-p120 Catenin is associated with discohesive infiltrative morphology in gastric and colonic carcinoma. Accumulation of p120 Catenin in the cytoplasm has been linked to lung cancer, pancreatic cancer, and gastric cancer, and is correlated to poor prognosis in colon cancer.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
CA-125 is normally found in epithelial cells of Fallopian tube, endometrium and endocervix, pancreas, colon, gall bladder, stomach, kidney, apocrine sweat gland, mammary gland, and mesothelial cell lining of pleura, pericardium, and the peritoneum. Anti-CA-125 reacts positively with ovarian malignancies, cervical carcinoma, seminal vesicle carcinoma, anaplastic lymphoma, and endometrial and bladder adenocarcinoma.
CA-125 is normally found in epithelial cells of Fallopian tube, endometrium and endocervix, pancreas, colon, gall bladder, stomach, kidney, apocrine sweat gland, mammary gland, and mesothelial cell lining of pleura, pericardium, and the peritoneum. Anti-CA-125 reacts positively with ovarian malignancies, cervical carcinoma, seminal vesicle carcinoma, anaplastic lymphoma, and endometrial and bladder adenocarcinoma.
CA-125 is normally found in epithelial cells of Fallopian tube, endometrium and endocervix, pancreas, colon, gall bladder, stomach, kidney, apocrine sweat gland, mammary gland, and mesothelial cell lining of pleura, pericardium, and the peritoneum. Anti-CA-125 reacts positively with ovarian malignancies, cervical carcinoma, seminal vesicle carcinoma, anaplastic lymphoma, and endometrial and bladder adenocarcinoma.
CA-125 is normally found in epithelial cells of Fallopian tube, endometrium and endocervix, pancreas, colon, gall bladder, stomach, kidney, apocrine sweat gland, mammary gland, and mesothelial cell lining of pleura, pericardium, and the peritoneum. Anti-CA-125 reacts positively with ovarian malignancies, cervical carcinoma, seminal vesicle carcinoma, anaplastic lymphoma, and endometrial and bladder adenocarcinoma.
Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin's lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin's lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin's lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
Cluster of Differentiation 30 (CD30) is a transmembrane cytokine receptor expressed by activated T- and B- cells. It is present on Reed-Sternberg cells in Hodgkin's lymphoma, most anaplastic large cell lymphomas, embryonal carcinomas, and primary cutaneous CD30 positive T-cell lymphoproliferative disorders. B-cell lymphomas are sometimes stained by Anti-CD30. Lymphomas exhibit Golgi zone accentuation when stained with Anti-CD30, while embryonal carcinomas produce membranous stains.
Isocitrate Dehydrogenase 1 (IDH1) is a soluble, cytoclic enzyme involved in the TCA metablic cycle. The most notable mutation in this enzyme, R132H, is clinically indicated in the majority of astrocytomas and oligodendroglial tumours, with the mutation being associated with more favourable prognosis and increased survival in those patients. IDH1 R132H is also useful in the differential diagnosis between anaplastic glioma and glioblastoma.
Isocitrate Dehydrogenase 1 (IDH1) is a soluble, cytoclic enzyme involved in the TCA metablic cycle. The most notable mutation in this enzyme, R132H, is clinically indicated in the majority of astrocytomas and oligodendroglial tumours, with the mutation being associated with more favourable prognosis and increased survival in those patients. IDH1 R132H is also useful in the differential diagnosis between anaplastic glioma and glioblastoma.
Isocitrate Dehydrogenase 1 (IDH1) is a soluble, cytoclic enzyme involved in the TCA metablic cycle. The most notable mutation in this enzyme, R132H, is clinically indicated in the majority of astrocytomas and oligodendroglial tumours, with the mutation being associated with more favourable prognosis and increased survival in those patients. IDH1 R132H is also useful in the differential diagnosis between anaplastic glioma and glioblastoma.
Isocitrate Dehydrogenase 1 (IDH1) is a soluble, cytoclic enzyme involved in the TCA metablic cycle. The most notable mutation in this enzyme, R132H, is clinically indicated in the majority of astrocytomas and oligodendroglial tumours, with the mutation being associated with more favourable prognosis and increased survival in those patients. IDH1 R132H is also useful in the differential diagnosis between anaplastic glioma and glioblastoma.
Cluster of Differentiation 138 (CD138), also known as Syndecan-1, is a trans- membrane glycoprotein present on the surface of B-cells during late stage differentiation. Anti-CD138 is used to differentiate marginal zone lymphoma from lymphoplasmacytic lymphoma. ALK+ Large B-Cell Lymphoma (LBCL) commonly stains positively for CD138, but not for CD20 and CD79a. Anti-CD138 reacts positively with HHV8-associated primary effusion lymphoma that lacks B-cell markers. CD138 is also a useful marker for identifying and enumerating benign, reactive, or malignant plasma cells from the bone marrow biopsy samples.
Cluster of Differentiation 138 (CD138), also known as Syndecan-1, is a trans- membrane glycoprotein present on the surface of B-cells during late stage differentiation. Anti-CD138 is used to differentiate marginal zone lymphoma from lymphoplasmacytic lymphoma. ALK+ Large B-Cell Lymphoma (LBCL) commonly stains positively for CD138, but not for CD20 and CD79a. Anti-CD138 reacts positively with HHV8-associated primary effusion lymphoma that lacks B-cell markers. CD138 is also a useful marker for identifying and enumerating benign, reactive, or malignant plasma cells from the bone marrow biopsy samples.
Cluster of Differentiation 138 (CD138), also known as Syndecan-1, is a trans- membrane glycoprotein present on the surface of B-cells during late stage differentiation. Anti-CD138 is used to differentiate marginal zone lymphoma from lymphoplasmacytic lymphoma. ALK+ Large B-Cell Lymphoma (LBCL) commonly stains positively for CD138, but not for CD20 and CD79a. Anti-CD138 reacts positively with HHV8-associated primary effusion lymphoma that lacks B-cell markers. CD138 is also a useful marker for identifying and enumerating benign, reactive, or malignant plasma cells from the bone marrow biopsy samples.
Cluster of Differentiation 138 (CD138), also known as Syndecan-1, is a trans- membrane glycoprotein present on the surface of B-cells during late stage differentiation. Anti-CD138 is used to differentiate marginal zone lymphoma from lymphoplasmacytic lymphoma. ALK+ Large B-Cell Lymphoma (LBCL) commonly stains positively for CD138, but not for CD20 and CD79a. Anti-CD138 reacts positively with HHV8-associated primary effusion lymphoma that lacks B-cell markers. CD138 is also a useful marker for identifying and enumerating benign, reactive, or malignant plasma cells from the bone marrow biopsy samples.
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which regulates T cell activity and immune response. OX40 is mainly activated by CD4 + and CD8 + T cells. It is expressed on cells, while OX40 ligands (OX40L, TNFSF4, CD252) are mainly expressed on activated antigen-presenting cells. Research shows that OX40 pathway is related to inflammation and autoimmune diseases. Other studies have shown that OX40 agonists can enhance the anti-tumor immunity of several cancer types.
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC144
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Benign Urothelium
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC144
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Benign Urothelium
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Rabbit
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC144
Antibody Isotype:
IgG
Application Details:
1:200
Regulatory Status:
RUO
Positive Control:
Benign Urothelium
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 44 (CD44) is a glycoprotein receptor for hyaluronic acid that plays a fundamental role in cellular adhesion, stromal binding, migration, and cell-cell interactions. Positive staining with Anti-CD44 is implicated in a multitude of different cancer types, including breast, prostatic, renal cell, colonic, hepatocellular, and genitourinary carcinomas, as well as non-Hodgkin's Lymphoma, metastatic melanoma, gastric cancer, and some soft tissue tumours. It has also been demonstrated that there is a positive correlation between tumour progression and increased expression of CD44v, a high molecular weight CD44 isoform that has been described in epithelial cells. Given the expression of CD44 in a wide range of cancers, the most practical application of CD44 immunostaining is its use in discriminating between urothelial transitional cell carcinoma <em>in situ</em> from non-neoplastic changes in the urothelium.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC145
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil, Lymph Node, Lymphoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC145
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil, Lymph Node, Lymphoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Predilute
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC145
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Tonsil, Lymph Node, Lymphoma
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 45 (CD45), also known as Leukocyte Common Antigen (LCA), is a member of the protein tyrosine phosphatase (PTPase) family that is known to regulate a variety of cellular processes including cell growth, differentiation, the mitotic cycle, and oncogenic transformation. CD45 is expressed in most nucleated cells of hematopoietic origin, and is an essential regulator of T- and B-cell antigen receptor signaling. Anti-CD45 positively stains the majority of lymphoid neoplasms, and is highly indicative of lymphoid origin. However, an absence of CD45 does not rule out lymphoid tumours, as certain types of neoplasms lack CD45, such as Hodgkin's lymphoma, some T-cell lymphomas, and some leukemias.
Product Type:
Positive Control Slides
Storage Temp:
-20 degrees Celsius
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Application Details:
1:200
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 163 (CD163) is a receptor found exclusively on the surface of monocytes and macrophages. The solubilized form in plasma is upregulated in inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and Gaucher’s disease, which supports recent studies that have found IL-10, glucocorticoids, and other inflammatory modulators to upregulate CD163 expression. CD163 staining is useful for differentiating synovial intimal fibroblasts from synovial macrophages in rheumatoid arthritis. Overexpression of CD163 is also present in patients with myelomonocytic leukemia dealing with microbial infections. CD163 expression is found in leukemias with monocytic differentiation and synovial-type giant cell tumours of the vertebral column.
Product Type:
Primary Antibody
Antibody Type:
Monoclonal
Format:
Concentrate
Storage Temp:
-20 degrees Celsius
Host Animal:
Mouse
Species Reactivity:
Human
Immunogen:
Recombinant Protein
Applications:
IHC
Clone number:
IHC163
Antibody Isotype:
IgG1
Application Details:
1:200
Regulatory Status:
CE-IVD
Positive Control:
Inflamed Tissue
Purification:
Affinity Purification
Buffer:
Tris Buffer pH7.6 with BSA, and sodium azide as preservative
Cluster of Differentiation 163 (CD163) is a receptor found exclusively on the surface of monocytes and macrophages. The solubilized form in plasma is upregulated in inflammatory diseases such as rheumatoid arthritis, atherosclerosis, and Gaucher’s disease, which supports recent studies that have found IL-10, glucocorticoids, and other inflammatory modulators to upregulate CD163 expression. CD163 staining is useful for differenti
